Feb. 24, 2020 13:55 UTC IRVINE, Calif.--( BUSINESS WIRE )-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that it has entered into an exchange agreement with three holders of the Company’s 3.25% Senior Convertible Notes due 2020 (the “Existing Notes”), pursuant to which these investors exchanged an aggregate of approximately $11.0 million of the Existing Notes plus accrued inte
February 24, 2020
· 18 min read